Endpoints News 27 ene 2026 CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Endpoints News 18 dic 2025 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Endpoints News 11 dic 2025 Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported